Autologous chondrocytes - ProChon Biotech
Alternative Names: BioCart; BioCartIILatest Information Update: 24 Oct 2021
At a glance
- Originator ProChon Biotech
- Developer Ocugen; ProChon Biotech
- Class Cell therapies
- Mechanism of Action Cartilage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Knee injuries
Most Recent Events
- 30 Sep 2019 Histogenics Corporation and Ocugen has merged to form Ocugen
- 16 May 2011 ProChon Biotech has been acquired by Histogenics Corporation
- 30 Jan 2001 Launched for Knee injuries in Israel (Implant)